1. Scrip
  2. >>Business
  3. >>Deals

Astellas Licenses 4D’s Viral Vector In Gene Therapy Push In Rare Ophthalmic Disease

Pays $20m Upfront

 
• By Ayisha Sharma

Under a broader push for strategic partnerships, the Japanese firm will use 4D’s tech to develop at least one intravitreal gene therapy for a rare eye disease as it emerges undeterred by previous challenges with the modality.  

scientist cutting dna strand graphic
The R100 Vector Can Penetrate The Retina's Inner Limiting Membrane Barrier • Source: Shutterstock
Key Takeaways:

  • The R100 vector is designed to penetrate the inner limiting membrane barrier of the retina.

  • 4D is eligible for a further $942.5m in option and milestone payments as well as royalties on sales.

  • Astellas is ramping up its partnership efforts after recent setbacks in the gene therapy space.

Astellas Pharma, Inc. is paying $20m upfront to get access to 4D Molecular Therapeutics Inc

The Japanese multinational will use 4D’s R100 vector to deliver its own payload for one genetic target in an undisclosed rare ophthalmic disease with the option to add two further targets for similar conditions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business